A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10–14 years old. Girls included in the immunogenicity subset in the primary controlled, observer-blinded, randomized study (NC...

Full description

Bibliographic Details
Main Authors: Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin, Frank Struyf
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hpv-16/18 as04-adjuvanted vaccine
hpv-31
hpv-45
non-vaccine types
cross-reactivity
immunogenicity persistence
safety
predictive modeling
Online Access:http://dx.doi.org/10.1080/21645515.2019.1625644

Internet

http://dx.doi.org/10.1080/21645515.2019.1625644

Similar Items